GlaxoSmithKline’s third-qtr results not as bad as expected

22 October 2014
gsk-whitty-big

UK pharma giant GlaxoSmithKline (LSE: GSK) has reported a downturn in both sales and profits for the third quarter of 2014, but the results were still better than expected in the face of patent expiries and its recent nearly $500 million fine for alleged bribery in China, and sent the company’s shares 4% higher following release of the figures.

The company reported a pretax profit of £548 million ($882.3 million) for the three months to end September, sharply down from £1.4 billion a year ago, but the results still beat analyst forecasts.

Sales were £5.65 billion, down 10% (3% lower at constant exchange rates), but below analysts’ forecasts of £5.75 billion. Core earnings per share were flat at 27.9 pence, compared with analyst forecasts of EPS of 23.9 pence, according to Thomson Reuters. Core operating profit came in a £1.89 billion, down 6% (-1% at CER).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical